Phospho-CHK1 (Ser345) Recombinant Rabbit Monoclonal Antibody (PS01-17), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | FEMA550715-Each-of-1 | In Stock | ₹ 42,275.00 |
FEMA550715 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 42,275.00
GST (18%): ₹ 7,609.50
Total Price: ₹ 49,884.50
Antigen
Phospho-CHK1 (Ser345)
Classification
Recombinant Monoclonal
Concentration
1 mg/mL
Formulation
PBS with 0.1% BSA, 40% glycerol and 0.05% sodium azide; pH 7.4
Gene Accession No.
O14757
Gene Symbols
Chek1
Immunogen
Synthetic peptide surrounding Ser345 of human Chk1/476.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Form
Liquid
Applications
Immunocytochemistry, Western Blot
Clone
PS01-17
Conjugate
Unconjugated
Gene
Chek1
Gene Alias
C85740, Cell cycle checkpoint kinase, checkpoint kinase 1, checkpoint kinase 1 homolog, checkpoint kinase-1, Checkpoint, S. pombe, homolog of, 1, CHEK1, CHK1, CHK1 checkpoint homolog, Chk1-S, homolog of Chk1-S, HRD1 Protein, rad27, rad27 homolog, serine/threonine protein kinase CHK1, serine/threonine-protein kinase Chk1, Synoviolin, YBR1742, YBR274W
Host Species
Rabbit
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
1111
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Isotype
IgG
Related Products
Description
- Positive control: HeLa treated with Etoposide cell lysate, HeLa treated with Hydroxyurea cell lysate, HeLa treated with 4mM Hydroxyurea for 20 hours
- Predicted band size: 54 kDa Subcellular Location: Nucleus, Chromosome, Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
- CHEK1 (CHK1) is a serine/threonine protein kinase involved in preventing replication when DNA integrity is compromised
- CHK1 is a key mediator in the DNA damage-induced checkpoint network
- CHK1 is an evolutionarily conserved protein kinase that functions to ensure genomic integrity upon genotoxic stress
- When the G2 or S checkpoint is abrogated by the inhibition of CHK1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase
- Thus, CHK1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient.